Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Neoadjuvant Carboplatin in Triple Negative Breast Cancer - A Prospective Phase II Study (NACATRINE Trial).

NCT02978495 is registered in ClinicalTrials.gov with Barretos Cancer Hospital as lead sponsor.

NCT NCT02978495
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02978495 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Neoadjuvant Carboplatin in Triple Negative Breast Cancer - A Prospective Phase II Study (NACATRINE Trial).
Lead sponsor
Barretos Cancer Hospital
Phase
Phase 2
Overall status
Completed
Start date
May 17, 2017
Completion date
October 22, 2021
Enrollment
154 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

brca1 hereditary breast and ovarian cancer syndrome